Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1678676
PUBLISHER: Grand View Research | PRODUCT CODE: 1678676
Nordic Regulatory Affairs Market Size, Share & Trends Analysis Report By Services, By Category, By Type, By Company Size, By Product Stage, By Indication, By End-use, By Country, And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Nordic Regulatory Affairs Market Growth & Trends:
The Nordic Regulatory Affairs market size is estimated to reach USD 890.7 million by 2030, registering a CAGR of 7.25% from 2025 to 2030, according to a new report by Grand View Research, Inc. An increase in R&D activities in countries such as Denmark and Norway, drug pipeline, and clinical trial applications are some of the key factors expected to drive the market.
Denmark is the hub of R&D activities in Europe. The country is known for its long tradition for collaborative R&D and the fastest approval of clinical trials makes it a preferred destination to perform drug discovery and development. Denmark also has the largest commercial drug-development pipeline in Europe. Thus, the urge for a faster drug approval process is one of the key factors expected to drive the market in the country.
In Sweden, as stated by the SwedenBIO, around 148 companies have 420 drug development projects; an increase by 51 projects compared to 2016. In addition, around 6% of the total exports from Sweden are related to pharmaceuticals. Hence, this is projected to create demand for regulatory affairs services in the country.
The ongoing COVID-19 pandemic is expected to create the need for regulatory affairs in the Nordic countries. Countries such as Sweden and Denmark, which are the hub of clinical trials, are expected to witness an increase in demand for regulatory services as many of the trials are put on hold. In addition to this, due to COVID-19, a significant number of vaccines and drugs are in the development stage, which requires faster approval. This is possible only through clearance by regulatory bodies. Thus, the need for regulatory affairs is expected to increase in the Nordic countries.
Nordic Regulatory Affairs Market Report Highlights:
- By service, the regulatory writing and publishing segment led the market in 2024, owing to an increase in the outsourcing of selected regulatory functions by major life sciences companies.
- Based on category, the biologics segment is projected to witness considerable growth during the forecast year, attributed to factors such as increasing R&D investments from pharmaceutical and biotechnology firms.
- Denmark regulatory affairs market accounted for the largest revenue share of 34.13% in 2024, owing to its strong pharmaceutical and biotechnology sector, supported by a well-established regulatory framework.
- Changing regulatory landscape, increasing need for companies to focus on core business activities, and economic and competitive pressures are the main factors responsible for the market growth.
Product Code: GVR-4-68039-331-1
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Type Segment
- 1.2.2. Services Segment
- 1.2.3. Category Segment
- 1.2.4. Indication Segment
- 1.2.5. Product Stage Segment
- 1.2.6. Company Size Segment
- 1.2.7. Indication Segment
- 1.2.8. End-use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Nordic Regulatory Affairs Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Changing Regulatory Landscape
- 3.2.1.2. Life Science Companies Focusing on Their Core Competencies
- 3.2.1.3. Economic and Competitive Pressures
- 3.2.1.4. Demand For the Faster Approval Process for Breakthrough Drugs and Devices
- 3.2.1.5. Growth in Emerging Areas Such as Personalized Medicine, Biosimilars, And Orphan Drugs
- 3.2.2. Market restraint analysis
- 3.2.2.1. Risk Associated with Data Security
- 3.2.2.2. Monitoring Issues and Lack of Standardization
- 3.2.1. Market driver analysis
- 3.3. Regulatory Affairs Market Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Nordic Regulatory Affairs Market: Services Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Nordic Regulatory Affairs Market Services Movement Analysis
- 4.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
- 4.4. Regulatory Consulting
- 4.4.1. Regulatory consulting market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Legal Representation
- 4.5.1. Legal representation market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Regulatory Writing & Publishing
- 4.6.1. Regulatory writing & publishing market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6.1.1. Writing
- 4.6.1.1.1. Writing market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6.1.2. Publishing
- 4.6.1.2.1. Publishing market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6.1.1. Writing
- 4.6.1. Regulatory writing & publishing market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.7. Product Registration & Clinical Trial Applications
- 4.7.1. Product registration & clinical trial applications market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.8. Other Services
- 4.8.1. Other services market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Nordic Regulatory Affairs Market: Category Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Nordic Regulatory Affairs Market Category Movement Analysis
- 5.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
- 5.4. Drugs
- 5.4.1. Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2. Innovators
- 5.4.2.1. Innovators market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2.2. Preclinical
- 5.4.2.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2.3. Clinical
- 5.4.2.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2.4. Pre-Market Approval (PMA)
- 5.4.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3. Generics
- 5.4.3.1. Generics market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3.2. Preclinical
- 5.4.3.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3.3. Clinical
- 5.4.3.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3.4. Pre-Market Approval (PMA)
- 5.4.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Biologics
- 5.5.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.2. Biotech
- 5.5.2.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.2.2. Preclinical
- 5.5.2.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.2.3. Clinical
- 5.5.2.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.2.4. Pre-Market Approval (PMA)
- 5.5.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.3. ATMP
- 5.5.3.1. ATMP market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.3.2. Preclinical
- 5.5.3.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.3.3. Clinical
- 5.5.3.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.3.4. Pre-Market Approval (PMA)
- 5.5.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Biosimilars
- 5.6.1. Biosimilars market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6.1.1. Preclinical
- 5.6.1.1.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6.1.2. Clinical
- 5.6.1.2.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6.1.3. Pre-Market Approval (PMA)
- 5.6.1.3.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6.1.1. Preclinical
- 5.6.1. Biosimilars market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Medical Devices
- 5.7.1. Medical devices market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.2. Diagnostics
- 5.7.2.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.2.2. Preclinical
- 5.7.2.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.2.3. Clinical
- 5.7.2.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.2.4. Pre-Market Approval (PMA)
- 5.7.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.3. Therapeutics
- 5.7.3.1. Therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.3.2. Preclinical
- 5.7.3.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.3.3. Clinical
- 5.7.3.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.3.4. Pre-Market Approval (PMA)
- 5.7.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Nordic Regulatory affairs market: Indication Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Nordic Regulatory Affairs Market Indication Movement Analysis
- 6.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
- 6.4. Oncology
- 6.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Neurology
- 6.5.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Cardiology
- 6.6.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.7. Immunology
- 6.7.1. Immunology market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.8. Others
- 6.8.1.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Nordic Regulatory Affairs Market: Product Stage Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Nordic Regulatory Affairs Market Product Stage Movement Analysis
- 7.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Product Stage, 2018 to 2030 (USD Million)
- 7.4. Preclinical
- 7.4.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5. Clinical studies
- 7.5.1. Clinical studies market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6. Pre-Market Approval (PMA)
- 7.6.1. PMA market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Nordic Regulatory Affairs Market: Type Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Nordic Regulatory Affairs Market Type Movement Analysis
- 8.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 8.4. In-house
- 8.4.1. In-house market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.5. Outsourced
- 8.5.1. Outsourced market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Nordic Regulatory Affairs Market: Company Size Estimates & Trend Analysis
- 9.2. Nordic Regulatory Affairs Market Company Size Movement Analysis
- 9.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Company Size, 2018 to 2030 (USD Million)
- 9.4. Small
- 9.4.1. Small market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5. Medium
- 9.5.1. Medium market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6. Large
- 9.6.1. Large market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Nordic Regulatory Affairs Market: End-use Estimates & Trend Analysis
- 10.1. Segment Dashboard
- 10.2. Nordic Regulatory Affairs Market End-use Movement Analysis
- 10.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
- 10.4. Medical Device Companies
- 10.4.1. Medical device companies market estimates and forecasts, 2018 to 2030 (USD Million)
- 10.5. Pharmaceutical Companies
- 10.5.1. Pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
- 10.6. Biotechnology Companies
- 10.6.1. Biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 11. Nordic Regulatory Affairs Market: Country Estimates & Trend Analysis
- 11.1. Country Market Share Analysis, 2024 & 2030
- 11.2. Country Market Dashboard
- 11.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 11.4. Denmark
- 11.4.1. Key country dynamics
- 11.4.2. Competitive scenario
- 11.4.3. Regulatory Scenario
- 11.4.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 11.5. Norway
- 11.5.1. Key country dynamics
- 11.5.2. Competitive scenario
- 11.5.3. Regulatory Scenario
- 11.5.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 11.6. Sweden
- 11.6.1. Key country dynamics
- 11.6.2. Competitive scenario
- 11.6.3. Regulatory Scenario
- 11.6.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 11.7. Finland
- 11.7.1. Key country dynamics
- 11.7.2. Competitive scenario
- 11.7.3. Regulatory Scenario
- 11.7.4. Finland market estimates and forecasts, 2018 to 2030 (USD Million)
- 11.8. Iceland
- 11.8.1. Key country dynamics
- 11.8.2. Competitive scenario
- 11.8.3. Regulatory Scenario
- 11.8.4. Iceland market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 12. Competitive Landscape
- 12.1. Company Categorization
- 12.2. Company Market Share/Assessment Analysis, 2024
- 12.3. Company Profiles
- 12.3.1. Pharma Assist Sweden AB
- 12.3.1.1. Company overview
- 12.3.1.2. Financial performance
- 12.3.1.3. Product benchmarking
- 12.3.1.4. Strategic initiatives
- 12.3.2. Genpact
- 12.3.2.1. Company overview
- 12.3.2.2. Financial performance
- 12.3.2.3. Product benchmarking
- 12.3.2.4. Strategic initiatives
- 12.3.3. Criterium, Inc.
- 12.3.3.1. Company overview
- 12.3.3.2. Financial performance
- 12.3.3.3. Product benchmarking
- 12.3.3.4. Strategic initiatives
- 12.3.4. ICON plc
- 12.3.4.1. Company overview
- 12.3.4.2. Financial performance
- 12.3.4.3. Product benchmarking
- 12.3.4.4. Strategic initiatives
- 12.3.5. Parexel International Corporation, Inc.
- 12.3.5.1. Company overview
- 12.3.5.2. Financial performance
- 12.3.5.3. Product benchmarking
- 12.3.5.4. Strategic initiatives
- 12.3.6. Global Pharma Consultancy AB
- 12.3.6.1. Company overview
- 12.3.6.2. Financial performance
- 12.3.6.3. Product benchmarking
- 12.3.6.4. Strategic initiatives
- 12.3.7. Freyr
- 12.3.7.1. Company overview
- 12.3.7.2. Financial performance
- 12.3.7.3. Product benchmarking
- 12.3.7.4. Strategic initiatives
- 12.3.8. Charles River Laboratories
- 12.3.8.1. Company overview
- 12.3.8.2. Financial performance
- 12.3.8.3. Product benchmarking
- 12.3.8.4. Strategic initiatives
- 12.3.9. Accell Clinical Research LLC
- 12.3.9.1. Company overview
- 12.3.9.2. Financial performance
- 12.3.9.3. Product benchmarking
- 12.3.9.4. Strategic initiatives
- 12.3.10. Regsmart Lifesciences AB
- 12.3.10.1. Company overview
- 12.3.10.2. Financial performance
- 12.3.10.3. Product benchmarking
- 12.3.10.4. Strategic initiatives
- 12.3.11. PHARMALEX GMBH
- 12.3.11.1. Company overview
- 12.3.11.2. Financial performance
- 12.3.11.3. Product benchmarking
- 12.3.11.4. Strategic initiatives
- 12.3.12. Pharmexon
- 12.3.12.1. Company overview
- 12.3.12.2. Financial performance
- 12.3.12.3. Product benchmarking
- 12.3.12.4. Strategic initiatives
- 12.3.1. Pharma Assist Sweden AB
Product Code: GVR-4-68039-331-1
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviations
- Table 3 Nordic Regulatory Affairs, by Services, 2018 - 2030 (USD Million)
- Table 4 Nordic Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
- Table 5 Nordic Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
- Table 6 Nordic Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Million)
- Table 7 Nordic Regulatory Affairs, by Type, 2018 - 2030 (USD Million)
- Table 8 Nordic Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
- Table 9 Nordic Regulatory Affairs, by End-Use, 2018 - 2030 (USD Million)
- Table 10 Nordic Regulatory Affairs, by Region, 2018 - 2030 (USD Million)
- Table 11 Denmark Regulatory Affairs, by Services, 2018 - 2030 (USD Million)
- Table 12 Denmark Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
- Table 13 Denmark Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
- Table 14 Denmark Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Million)
- Table 15 Denmark Regulatory Affairs, by Type, 2018 - 2030 (USD Million)
- Table 16 Denmark Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
- Table 17 Denmark Regulatory Affairs, by End-Use, 2018 - 2030 (USD Million)
- Table 18 Norway Regulatory Affairs, by Services, 2018 - 2030 (USD Million)
- Table 19 Norway Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
- Table 20 Norway Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
- Table 21 Norway Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Million)
- Table 22 Norway Regulatory Affairs, by Type, 2018 - 2030 (USD Million)
- Table 23 Norway Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
- Table 24 Norway Regulatory Affairs, by End-Use, 2018 - 2030 (USD Million)
- Table 25 Finland Regulatory Affairs, by Services, 2018 - 2030 (USD Million)
- Table 26 Finland Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
- Table 27 Finland Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
- Table 28 Finland Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Million)
- Table 29 Finland Regulatory Affairs, by Type, 2018 - 2030 (USD Million)
- Table 30 Finland Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
- Table 31 Finland Regulatory Affairs, by End-Use, 2018 - 2030 (USD Million)
- Table 32 Iceland Regulatory Affairs, by Services, 2018 - 2030 (USD Million)
- Table 33 Iceland Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
- Table 34 Iceland Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
- Table 35 Iceland Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Million)
- Table 36 Iceland Regulatory Affairs, by Type, 2018 - 2030 (USD Million)
- Table 37 Iceland Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
- Table 38 Iceland Regulatory Affairs, by End-Use, 2018 - 2030 (USD Million)
- Table 39 Sweden Regulatory Affairs, by Services, 2018 - 2030 (USD Million)
- Table 40 Sweden Regulatory Affairs, by Category, 2018 - 2030 (USD Million)
- Table 41 Sweden Regulatory Affairs, by Indication, 2018 - 2030 (USD Million)
- Table 42 Sweden Regulatory Affairs, by Product Stage, 2018 - 2030 (USD Million)
- Table 43 Sweden Regulatory Affairs, by Type, 2018 - 2030 (USD Million)
- Table 44 Sweden Regulatory Affairs, by Company Size, 2018 - 2030 (USD Million)
- Table 45 Sweden Regulatory Affairs, by End-Use, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Regulatory Affairs Market segmentation
- Fig. 2 Data analysis models
- Fig. 3 Market formulation and validation
- Fig. 4 Data validating & publishing
- Fig. 5 Market research process
- Fig. 6 Information procurement
- Fig. 7 Primary research
- Fig. 8 Value-chain-based sizing & forecasting
- Fig. 9 QFD modelling for market share assessment
- Fig. 10 Market formulation & validation
- Fig. 11 Commodity flow analysis
- Fig. 12 Market outlook
- Fig. 13 Segment snapshot 1
- Fig. 14 Segment snapshot 2
- Fig. 15 Competitive landscape snapshot
- Fig. 16 Market trends & outlook
- Fig. 17 Porter's five force analysis
- Fig. 18 PESTEL analysis
- Fig. 19 Regulatory Affairs Market: Services outlook key takeaways
- Fig. 20 Regulatory Affairs Market: Services movement analysis
- Fig. 21 Regulatory consulting market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 22 Legal representation market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 23 Regulatory writing & publishing market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 24 Writing market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 25 Publishing market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 26 Product registration & clinical trial applications market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 27 Other services market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 28 Regulatory Affairs Market: Category outlook key takeaways
- Fig. 29 Regulatory Affairs Market: Category movement analysis
- Fig. 30 Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 31 Innovators drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 32 Preclinical innovator drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 33 Clinical innovator drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 34 Pre-Market Approval (PMA) innovator drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 35 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 36 Preclinical generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 37 Clinical generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 38 Pre-Market Approval (PMA) generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 39 Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 40 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 41 Preclinical biotech market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 42 Clinical biotech market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 43 Pre-Market Approval (PMA) biotech market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 44 ATMP market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 45 Preclinical ATMP market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 46 Clinical ATMP market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 47 Pre-Market Approval (PMA) ATMP market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 48 Biosimilars market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 49 Preclinical biosimilars market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 50 Clinical biosimilars market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 51 Pre-Market Approval (PMA) biosimilars market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 52 Medical Devices market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 53 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 54 Preclinical diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 55 Clinical diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 56 Pre-Market Approval (PMA) diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 57 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 58 Preclinical therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 59 Clinical therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 60 Pre-Market Approval (PMA) therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 61 Regulatory affairs market: Indication outlook key takeaways
- Fig. 62 Regulatory affairs market: Indication movement analysis
- Fig. 63 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 64 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 65 Cardiology companies market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 66 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 67 Others market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 68 Regulatory affairs market: Product stage outlook key takeaways
- Fig. 69 Regulatory affairs market: Product stage movement analysis
- Fig. 70 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 71 Clinical studies market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 72 PMA companies market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 73 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 74 Regulatory affairs market: Type outlook key takeaways
- Fig. 75 Regulatory affairs market: Type movement analysis
- Fig. 76 In-house market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 77 Outsourced market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 78 Regulatory affairs market: Company size outlook key takeaways
- Fig. 79 Regulatory affairs market: Company size movement analysis
- Fig. 80 Small market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 81 Medium market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 82 Large market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 83 Regulatory affairs market: End-use outlook key takeaways
- Fig. 84 Regulatory affairs market: End-use movement analysis
- Fig. 85 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 86 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 87 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 88 Country outlook, 2024 & 2030 (USD Million)
- Fig. 89 Country marketplace: Key takeaways
- Fig. 90 Key country dynamics
- Fig. 91 Denmark Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 92 Key country dynamics
- Fig. 93 Sweden Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 94 Key country dynamics
- Fig. 95 Norway Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 96 Key country dynamics
- Fig. 97 Finland regulatory affairs market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 98 Key country dynamics
- Fig. 99 Iceland Regulatory Affairs Market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 100 Market participant categorization
- Fig. 101 Regulatory affairs market share/assessment analysis, 2024
- Fig. 102 Strategic framework
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.